Shenzhen Hepalink Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Hepalink Pharmaceutical Company Limited with three other
companies in this sector in China:
ChangChun High New Technology Industries
sales of 2.37 billion Chinese Renmimbi [US$343.72 million]
of which 79%
Shanxi Zhendong Pharmaceutical Co Ltd
(2.26 billion Chinese Renmimbi [US$327.39 million]
of which 95%
was Medicine Manufacture and Sale), and
Zhejiang Jianfeng Group Company Limited
(2.26 billion Chinese Renmimbi [US$326.79 million]
of which 45%
During the year ended December of 2015, sales at
Shenzhen Hepalink Pharmaceutical Company Limited were 2.29 billion Chinese Renmimbi (US$331.40 million).
increase of 17.0%
versus 2014, when the company's sales were 1.96 billion Chinese Renmimbi.
Sales of Other Operating saw an increase
that was more than double the company's growth rate: sales were up
221.9% in 2015, from
376,626.15 Chinese Renmimbi to 1.21 million Chinese Renmimbi.